Eli Lilly (LLY)
(Delayed Data from NYSE)
$811.53 USD
+3.67 (0.45%)
Updated May 29, 2024 04:00 PM ET
After-Market: $810.68 -0.85 (-0.10%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Price, Consensus and EPS Surprise
LLY 811.53 +3.67(0.45%)
Will LLY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LLY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LLY
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Eli Lilly (LLY) to Ramp Up Indiana Site for Mounjaro, Zepbound
LLY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
Lilly (LLY) Hits Record High on Crohn's Disease Study Data
Other News for LLY
Lilly's Retevmo gains approval for children as young as two with thyroid cancer
FDA grants Lilly's Retevmo accelerated approval for thyroid cancer
Ro provides supply tracking feature for Lilly, Novo Nordisk weight loss drugs
Harding Loevner International Equity ADR Composite Q1 2024 Report
Harding Loevner International Equity Composite Q1 2024 Report